During the last session, Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)’s traded shares were 1.05 million, with the beta value of the company hitting 1.89. At the end of the trading day, the stock’s price was $13.91, reflecting an intraday gain of 15.92% or $1.91. The 52-week high for the RCKT share is $49.66, that puts it down -257.01 from that peak though still a striking 45.58% gain since the share price plummeted to a 52-week low of $7.57. The company’s market capitalization is $812.90M, and the average intraday trading volume over the past 10 days was 0.89 million shares, and the average trade volume was 747.58K shares over the past three months.
Rocket Pharmaceuticals Inc. (RCKT) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.70. RCKT has a Sell rating from 0 analyst(s) out of 11 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 11 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.68.
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) trade information
Rocket Pharmaceuticals Inc. (RCKT) registered a 15.92% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 15.92% in intraday trading to $13.91 this Thursday, 06/23/22, hitting a weekly high. The stock’s 5-day price performance is 26.68%, and it has moved by 28.32% in 30 days. Based on these gigs, the overall price performance for the year is -67.64%. The short interest in Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is 7.56 million shares and it means that shorts have 15.96 day(s) to cover.
The consensus price target of analysts on Wall Street is $56.44, which implies an increase of 75.35% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $33.00 and $67.00 respectively. As a result, RCKT is trading at a discount of -381.67% off the target high and -137.24% off the low.
Rocket Pharmaceuticals Inc. (RCKT) estimates and forecasts
Statistics show that Rocket Pharmaceuticals Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Rocket Pharmaceuticals Inc. (RCKT) shares have gone down -40.40% during the last six months, with a year-to-date growth rate less than the industry average at -1.12% against 1.00. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -23.60% this quarter and then jump 11.40% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -19.30%. While earnings are projected to return -6.00% in 2022.
Rocket Pharmaceuticals Inc. is due to release its next quarterly earnings between August 08 and August 12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)’s Major holders
Rocket Pharmaceuticals Inc. insiders own 4.40% of total outstanding shares while institutional holders control 99.02%, with the float percentage being 103.57%. RTW Investments LP is the largest shareholder of the company, while 238 institutions own stock in it. As of Dec 30, 2021, the company held over 15.8 million shares (or 24.00% of all shares), a total value of $344.98 million in shares.
The next largest institutional holding, with 3.49 million shares, is of Wellington Management Group, LLP’s that is approximately 5.30% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $76.21 million.
Also, the Mutual Funds coming in first place with the largest holdings of Rocket Pharmaceuticals Inc. (RCKT) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. Data provided on Jan 30, 2022 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 1.69 million shares. This amounts to just over 2.57 percent of the company’s overall shares, with a $28.12 million market value. The same data shows that the other fund manager holds slightly less at 1.29 million, or about 1.96% of the stock, which is worth about $28.16 million.